Multiple-Dose Pharmacokinetics and Pharmacodynamics of Adinazolam in Elderly Subjects

  title={Multiple-Dose Pharmacokinetics and Pharmacodynamics of Adinazolam in Elderly Subjects},
  author={Joseph C. Fleishaker and Jack P. Phillips and T. Caitlin M. Smith and Randall B. Smith},
  journal={Pharmaceutical Research},
The pharmacokinetics and pharmacodynamics of adinazolam (AD) were evaluated in 21 elderly subjects (mean age, 69 ± 4 years) at four dose levels during a placebo-controlled, double-blind, dose escalation regimen in which the oral dose was varied from 10 to 60 mg daily, in divided doses. Fifteen subjects received adinazolam mesylate; six received placebo. Plasma samples collected during a single dosing interval in each dosing period (3 days) were assayed for adinazolam and monodesmethyl… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-9 of 9 extracted citations

Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.

Drug metabolism and disposition: the biological fate of chemicals • 2010
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…